(CercleFinance.com) – AstraZeneca announced Monday that the CHMP had issued a favorable opinion with a view to granting marketing authorization in the European Union for Voydeya, its treatment for paroxysmal nocturnal hemoglobinuria ( HPN).
The CHMP’s positive opinion concerns the treatment of adult patients suffering from the form of the disease characterized by residual hemolytic anemia, the laboratory specifies in a press release.
This factor D inhibitor, administered orally, was developed as a complementary treatment to standard therapy, which generally relies on Ultomiris and Soliris, two drugs already owned by AstraZeneca, for the management of this specific indication which represents between 10% and 20% of people affected by PNH.
The pathology manifests itself as vascular thrombosis which can cause symptoms such as abdominal pain or headaches, in addition to swelling of the legs or arms.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
